{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:21:45Z","timestamp":1740144105973,"version":"3.37.3"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13063-017-2343-3","type":"journal-article","created":{"date-parts":[[2018,2,12]],"date-time":"2018-02-12T07:56:33Z","timestamp":1518422193000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Resistant Hypertension On Treatment (ResHypOT): sequential nephron blockade compared to dual blockade of the renin-angiotensin-aldosterone system plus bisoprolol in the treatment of resistant arterial hypertension \u2013 study protocol for a randomized controlled trial"],"prefix":"10.1186","volume":"19","author":[{"given":"Elizabeth do Espirito Santo","family":"Cest\u00e1rio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Let\u00edcia Aparecida Barufi","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luiz Tadeu","family":"Giollo-J\u00fanior","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e9ssica Rodrigues Roma","family":"Uyemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camila Suemi Sato","family":"Matarucco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manoel Idelfonso Paz","family":"Landim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luciana Neves","family":"Cosenso-Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00facia Helena Bonalume","family":"T\u00e1cito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heitor","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Fernando","family":"Vilela-Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Carlos","family":"Yugar-Toledo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,2,12]]},"reference":[{"issue":"20","key":"2343_CR1","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1001\/jama.1996.03530440051036","volume":"275","author":"WB Kannel","year":"1996","unstructured":"Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA. 1996;275(20):1571\u20136.","journal-title":"JAMA"},{"issue":"1 Pt 2","key":"2343_CR2","doi-asserted-by":"publisher","first-page":"3S","DOI":"10.1016\/S0895-7061(99)00252-6","volume":"13","author":"WB Kannel","year":"2000","unstructured":"Kannel WB. Risk stratification in hypertension: new insights from the Framingham Study. Am J Hypertens. 2000;13(1 Pt 2):3S\u201310.","journal-title":"Am J Hypertens"},{"issue":"3","key":"2343_CR3","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1161\/HYPERTENSIONAHA.116.08249","volume":"69","author":"KN Karmali","year":"2017","unstructured":"Karmali KN, Lloyd-Jones DM. Global risk assessment to guide blood pressure management in cardiovascular disease prevention. Hypertension. 2017;69(3):e2\u20139.","journal-title":"Hypertension"},{"issue":"9349","key":"2343_CR4","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1016\/S0140-6736(02)11911-8","volume":"360","author":"S Lewington","year":"2002","unstructured":"Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903\u201313.","journal-title":"Lancet"},{"key":"2343_CR5","doi-asserted-by":"crossref","unstructured":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981-97.","DOI":"10.1001\/jama.288.23.2981"},{"issue":"4","key":"2343_CR6","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.amjmed.2016.10.002","volume":"130","author":"S Bangalore","year":"2017","unstructured":"Bangalore S, Davis BR, Cushman WC, Pressel SL, Muntner PM, Calhoun DA, et al. Treatment-resistant hypertension and outcomes based on randomized treatment group in ALLHAT. Am J Med. 2017;130(4):439\u201348. e9.","journal-title":"Am J Med"},{"issue":"22","key":"2343_CR7","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1001\/archinte.167.22.2431","volume":"167","author":"ND Wong","year":"2007","unstructured":"Wong ND, Lopez VA, L\u2019Italien G, Chen R, Kline SE, Franklin SS. Inadequate control of hypertension in US adults with cardiovascular disease comorbidities in 2003\u20132004. Arch Intern Med. 2007;167(22):2431\u20136.","journal-title":"Arch Intern Med"},{"issue":"1","key":"2343_CR8","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/HJH.0b013e32834d9eda","volume":"30","author":"MJ Prince","year":"2012","unstructured":"Prince MJ, Ebrahim S, Acosta D, Ferri CP, Guerra M, Huang Y, et al. Hypertension prevalence, awareness, treatment and control among older people in Latin America, India and China: a 10\/66 cross-sectional population-based survey. J Hypertens. 2012;30(1):177\u201387.","journal-title":"J Hypertens"},{"issue":"6","key":"2343_CR9","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1590\/S0066-782X2009001200018","volume":"93","author":"TM Rosario","year":"2009","unstructured":"Rosario TM, Scala LC, Franca GV, Pereira MR, Jardim PC. Prevalence, control and treatment of arterial hypertension in Nobres \u2013 MT. Arq Bras Cardiol. 2009;93(6):622\u20138. 72-8.","journal-title":"Arq Bras Cardiol"},{"issue":"6","key":"2343_CR10","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1161\/HYPERTENSIONAHA.108.189141","volume":"51","author":"DA Calhoun","year":"2008","unstructured":"Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008;51(6):1403\u201319.","journal-title":"Hypertension"},{"issue":"1","key":"2343_CR11","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1097\/MNH.0000000000000286","volume":"26","author":"M Siddiqui","year":"2017","unstructured":"Siddiqui M, Calhoun DA. Refractory versus resistant hypertension. Curr Opin Nephrol Hypertens. 2017;26(1):14\u20139.","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"1","key":"2343_CR12","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1161\/HYPERTENSIONAHA.117.08929","volume":"70","author":"A Cai","year":"2017","unstructured":"Cai A, Calhoun DA. Resistant hypertension: an update of experimental and clinical findings. Hypertension. 2017;70(1):5\u20139.","journal-title":"Hypertension"},{"issue":"5","key":"2343_CR13","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.cjca.2015.06.033","volume":"32","author":"M Siddiqui","year":"2016","unstructured":"Siddiqui M, Dudenbostel T, Calhoun DA. Resistant and refractory hypertension: antihypertensive treatment resistance vs treatment failure. Can J Cardiol. 2016;32(5):603\u20136.","journal-title":"Can J Cardiol"},{"issue":"6","key":"2343_CR14","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1161\/HYPERTENSIONAHA.116.06587","volume":"67","author":"T Dudenbostel","year":"2016","unstructured":"Dudenbostel T, Siddiqui M, Oparil S, Calhoun DA. Refractory hypertension: a novel phenotype of antihypertensive treatment failure. Hypertension. 2016;67(6):1085\u201392.","journal-title":"Hypertension"},{"issue":"5","key":"2343_CR15","doi-asserted-by":"publisher","first-page":"593","DOI":"10.4070\/kcj.2016.46.5.593","volume":"46","author":"DA Calhoun","year":"2016","unstructured":"Calhoun DA. Refractory and resistant hypertension: antihypertensive treatment failure versus treatment resistance. Korean Circ J. 2016;46(5):593\u2013600.","journal-title":"Korean Circ J"},{"issue":"5","key":"2343_CR16","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.jash.2015.03.005","volume":"9","author":"R Modolo","year":"2015","unstructured":"Modolo R, de Faria AP, Sabbatini AR, Barbaro NR, Ritter AM, Moreno H. Refractory and resistant hypertension: characteristics and differences observed in a specialized clinic. J Am Soc Hypertens. 2015;9(5):397\u2013402.","journal-title":"J Am Soc Hypertens"},{"issue":"9","key":"2343_CR17","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/jhh.2014.128","volume":"29","author":"L Boswell","year":"2015","unstructured":"Boswell L, Pascual J, Oliveras A. Resistant hypertension: do all definitions describe the same patients? J Hum Hypertens. 2015;29(9):530\u20134.","journal-title":"J Hum Hypertens"},{"issue":"21","key":"2343_CR18","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1001\/jama.2014.5180","volume":"311","author":"W Vongpatanasin","year":"2014","unstructured":"Vongpatanasin W. Resistant hypertension: a review of diagnosis and management. JAMA. 2014;311(21):2216\u201324.","journal-title":"JAMA"},{"issue":"7","key":"2343_CR19","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1097\/HJH.0000000000000219","volume":"32","author":"R Modolo","year":"2014","unstructured":"Modolo R, de Faria AP, Sabbatini AR, Moreno H. Resistant hypertension revisited: definition and true prevalence. J Hypertens. 2014;32(7):1546.","journal-title":"J Hypertens"},{"issue":"3","key":"2343_CR20","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1161\/HYPERTENSIONAHA.113.02026","volume":"63","author":"DA Calhoun","year":"2014","unstructured":"Calhoun DA, Booth 3rd JN, Oparil S, Irvin MR, Shimbo D, Lackland DT, et al. Refractory hypertension: determination of prevalence, risk factors, and comorbidities in a large, population-based cohort. Hypertension. 2014;63(3):451\u20138.","journal-title":"Hypertension"},{"issue":"10","key":"2343_CR21","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.mayocp.2013.06.017","volume":"88","author":"JJ Sim","year":"2013","unstructured":"Sim JJ, Bhandari SK, Shi J, Liu IL, Calhoun DA, McGlynn EA, et al. Characteristics of resistant hypertension in a large, ethnically diverse hypertension population of an integrated health system. Mayo Clin Proc. 2013;88(10):1099\u2013107.","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"2343_CR22","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3109\/08037051.2012.701419","volume":"21","author":"H Moreno Jr","year":"2012","unstructured":"Moreno Jr H, Coca A. Resistant and refractory hypertension: reflections on pathophysiology and terminology. Blood Press. 2012;21(4):209\u201310.","journal-title":"Blood Press"},{"issue":"1","key":"2343_CR23","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1590\/S0066-782X2012000700002","volume":"99","author":"A Alessi","year":"2012","unstructured":"Alessi A, Brandao AA, Coca A, Cordeiro AC, Nogueira AR, de Magalhaes DF, et al. First Brazilian position on resistant hypertension. Arq Bras Cardiol. 2012;99(1):576\u201385.","journal-title":"Arq Bras Cardiol"},{"issue":"5","key":"2343_CR24","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1161\/HYPERTENSIONAHA.110.168948","volume":"57","author":"A Sierra de la","year":"2011","unstructured":"de la Sierra A, Segura J, Banegas JR, Gorostidi M, de la Cruz JJ, Armario P, et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension. 2011;57(5):898\u2013902.","journal-title":"Hypertension"},{"issue":"6","key":"2343_CR25","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1161\/HYPERTENSIONAHA.111.170308","volume":"57","author":"SD Persell","year":"2011","unstructured":"Persell SD. Prevalence of resistant hypertension in the United States, 2003\u20132008. Hypertension. 2011;57(6):1076\u201380.","journal-title":"Hypertension"},{"issue":"13","key":"2343_CR26","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1161\/CIRCULATIONAHA.111.068064","volume":"125","author":"SL Daugherty","year":"2012","unstructured":"Daugherty SL, Powers JD, Magid DJ, Tavel HM, Masoudi FA, Margolis KL, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012;125(13):1635\u201342.","journal-title":"Circulation"},{"key":"2343_CR27","volume-title":"Pharmacotherapy for resistant hypertension in adults","author":"J Charan","year":"2017","unstructured":"Charan J, Chaudhari M, Mulla S, Reljic T, Mhaskar R, Kumar A. Pharmacotherapy for resistant hypertension in adults. 2017."},{"issue":"8","key":"2343_CR28","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.tcm.2016.05.004","volume":"26","author":"A Eirin","year":"2016","unstructured":"Eirin A, Textor SC, Lerman LO. Emerging concepts for patients with treatment-resistant hypertension. Trends Cardiovasc Med. 2016;26(8):700\u20136.","journal-title":"Trends Cardiovasc Med"},{"key":"2343_CR29","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ahj.2017.01.008","volume":"186","author":"S Vemulapalli","year":"2017","unstructured":"Vemulapalli S, Deng L, Patel MR, Kilgore ML, Jones WS, Curtis LH, et al. National patterns in intensity and frequency of outpatient care for apparent treatment-resistant hypertension. Am Heart J. 2017;186:29\u201339.","journal-title":"Am Heart J"},{"issue":"4","key":"2343_CR30","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1161\/HYPERTENSIONAHA.117.08924","volume":"69","author":"H Sternlicht","year":"2017","unstructured":"Sternlicht H, Bakris GL. Resistant hypertension: a refractory disease or refractory patient. Hypertension. 2017;69(4):582\u20133.","journal-title":"Hypertension"},{"issue":"9912","key":"2343_CR31","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/S0140-6736(13)62229-1","volume":"383","author":"I Chalmers","year":"2014","unstructured":"Chalmers I, Bracken MB, Djulbegovic B, Garattini S, Grant J, G\u00fclmezoglu AM, et al. How to increase value and reduce waste when research priorities are set. Lancet. 2014;383(9912):156\u201365. doi:\n                    https:\/\/doi.org\/10.1016\/S0140-6736(13)62229-1\n                    \n                  .","journal-title":"Lancet"},{"issue":"5","key":"2343_CR32","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1161\/01.HYP.0000016176.16042.2F","volume":"39","author":"SJ Taler","year":"2002","unstructured":"Taler SJ, Textor SC, Augustine JE. Resistant hypertension: comparing hemodynamic management to specialist care. Hypertension. 2002;39(5):982\u20138.","journal-title":"Hypertension"},{"issue":"11","key":"2343_CR33","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1001\/archinte.168.11.1159","volume":"168","author":"KK Gaddam","year":"2008","unstructured":"Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, Pimenta E, Aban I, Oparil S, et al. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med. 2008;168(11):1159\u201364.","journal-title":"Arch Intern Med"},{"issue":"3","key":"2343_CR34","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1161\/HYPERTENSIONAHA.109.131235","volume":"54","author":"E Pimenta","year":"2009","unstructured":"Pimenta E, Gaddam KK, Oparil S, Aban I, Husain S, Dell\u2019Italia LJ, et al. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension. 2009;54(3):475\u201381.","journal-title":"Hypertension"},{"issue":"11","key":"2343_CR35","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1097\/00004872-200411000-00026","volume":"22","author":"IK Eide","year":"2004","unstructured":"Eide IK, Torjesen PA, Drolsum A, Babovic A, Lilledahl NP. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens. 2004;22(11):2217\u201326.","journal-title":"J Hypertens"},{"issue":"8","key":"2343_CR36","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/hr.2013.69","volume":"36","author":"T Shimosawa","year":"2013","unstructured":"Shimosawa T. Salt, the renin-angiotensin-aldosterone system and resistant hypertension. Hypertens Res. 2013;36(8):657\u201360.","journal-title":"Hypertens Res"},{"issue":"11","key":"2343_CR37","doi-asserted-by":"publisher","first-page":"4041","DOI":"10.1093\/ndt\/gfs384","volume":"27","author":"R Agarwal","year":"2012","unstructured":"Agarwal R. Resistant hypertension and the neglected antihypertensive: sodium restriction. Nephrol Dial Transplant. 2012;27(11):4041\u20135.","journal-title":"Nephrol Dial Transplant"},{"key":"2343_CR38","doi-asserted-by":"publisher","first-page":"642416","DOI":"10.4061\/2011\/642416","volume":"2011","author":"C Tsioufis","year":"2011","unstructured":"Tsioufis C, Kordalis A, Flessas D, Anastasopoulos I, Tsiachris D, Papademetriou V, et al. Pathophysiology of resistant hypertension: the role of sympathetic nervous system. Int J Hypertens. 2011;2011:642416.","journal-title":"Int J Hypertens"},{"issue":"1","key":"2343_CR39","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1161\/HYPERTENSIONAHA.115.05449","volume":"66","author":"T Dudenbostel","year":"2015","unstructured":"Dudenbostel T, Acelajado MC, Pisoni R, Li P, Oparil S, Calhoun DA. Refractory hypertension: evidence of heightened sympathetic activity as a cause of antihypertensive treatment failure. Hypertension. 2015;66(1):126\u201333.","journal-title":"Hypertension"},{"issue":"4 Pt 1","key":"2343_CR40","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/S0895-7061(01)02342-1","volume":"15","author":"J Ouzan","year":"2002","unstructured":"Ouzan J, Perault C, Lincoff AM, Carre E, Mertes M. The role of spironolactone in the treatment of patients with refractory hypertension. Am J Hypertens. 2002;15(4 Pt 1):333\u20139.","journal-title":"Am J Hypertens"},{"issue":"1","key":"2343_CR41","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.amjhyper.2004.08.026","volume":"18","author":"A Mahmud","year":"2005","unstructured":"Mahmud A, Feely J. Aldosterone-to-renin ratio, arterial stiffness, and the response to aldosterone antagonism in essential hypertension. Am J Hypertens. 2005;18(1):50\u20135.","journal-title":"Am J Hypertens"},{"issue":"12 Pt 1","key":"2343_CR42","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1016\/j.amjhyper.2005.06.010","volume":"18","author":"A Mahmud","year":"2005","unstructured":"Mahmud A, Mahgoub M, Hall M, Feely J. Does aldosterone-to-renin ratio predict the antihypertensive effect of the aldosterone antagonist spironolactone? Am J Hypertens. 2005;18(12 Pt 1):1631\u20135.","journal-title":"Am J Hypertens"},{"issue":"2","key":"2343_CR43","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.cpcardiol.2008.10.002","volume":"34","author":"KK Gaddam","year":"2009","unstructured":"Gaddam KK, Pimenta E, Husain S, Calhoun DA. Aldosterone and cardiovascular disease. Curr Probl Cardiol. 2009;34(2):51\u201384.","journal-title":"Curr Probl Cardiol"},{"issue":"5","key":"2343_CR44","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s11906-007-0066-7","volume":"9","author":"E Pimenta","year":"2007","unstructured":"Pimenta E, Calhoun DA. Resistant hypertension and aldosteronism. Curr Hypertens Rep. 2007;9(5):353\u20139.","journal-title":"Curr Hypertens Rep"},{"issue":"10","key":"2343_CR45","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.hlc.2016.02.016","volume":"25","author":"C Wang","year":"2016","unstructured":"Wang C, Xiong B, Huang J. Efficacy and safety of spironolactone in patients with resistant hypertension: a meta-analysis of randomised controlled trials. Heart Lung Circ. 2016;25(10):1021\u201330.","journal-title":"Heart Lung Circ"},{"issue":"8","key":"2343_CR46","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1097\/HJH.0b013e3283551e98","volume":"30","author":"G Bobrie","year":"2012","unstructured":"Bobrie G, Frank M, Azizi M, Peyrard S, Boutouyrie P, Chatellier G, et al. Sequential nephron blockade versus sequential renin-angiotensin system blockade in resistant hypertension: a prospective, randomized, open blinded endpoint study. J Hypertens. 2012;30(8):1656\u201364.","journal-title":"J Hypertens"},{"issue":"12","key":"2343_CR47","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1097\/HJH.0000000000000737","volume":"33","author":"H Beaussier","year":"2015","unstructured":"Beaussier H, Boutouyrie P, Bobrie G, Frank M, Laurent S, Coudore F, et al. True antihypertensive efficacy of sequential nephron blockade in patients with resistant hypertension and confirmed medication adherence. J Hypertens. 2015;33(12):2526\u201333.","journal-title":"J Hypertens"},{"issue":"2","key":"2343_CR48","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1093\/ajh\/hpw105","volume":"30","author":"T Dudenbostel","year":"2017","unstructured":"Dudenbostel T, Calhoun DA. Use of aldosterone antagonists for treatment of uncontrolled resistant hypertension. Am J Hypertens. 2017;30(2):103\u20139.","journal-title":"Am J Hypertens"},{"issue":"3","key":"2343_CR49","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/j.1751-7176.2008.08143.x","volume":"10","author":"E Pimenta","year":"2008","unstructured":"Pimenta E, Gaddam KK, Oparil S. Mechanisms and treatment of resistant hypertension. J Clin Hypertens (Greenwich). 2008;10(3):239\u201344.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"2343_CR50","first-page":"895401","volume":"2014","author":"E Hur","year":"2014","unstructured":"Hur E, Ozisik M, Ural C, Yildiz G, Magden K, Kose SB, et al. Hypervolemia for hypertension pathophysiology: a population-based study. Biomed Res Int. 2014;2014:895401.","journal-title":"Biomed Res Int"},{"issue":"11","key":"2343_CR51","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1038\/ajh.2011.171","volume":"24","author":"JH Laragh","year":"2011","unstructured":"Laragh JH, Sealey JE. The plasma renin test reveals the contribution of body sodium-volume content (V) and renin-angiotensin (R) vasoconstriction to long-term blood pressure. Am J Hypertens. 2011;24(11):1164\u201380. doi:\n                    https:\/\/doi.org\/10.1038\/ajh.2011.171\n                    \n                  .","journal-title":"Am J Hypertens"},{"issue":"8","key":"2343_CR52","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s11906-016-0671-4","volume":"18","author":"P Li","year":"2016","unstructured":"Li P, Nader M, Arunagiri K, Papademetriou V. Device-based therapy for drug-resistant hypertension: an update. Curr Hypertens Rep. 2016;18(8):64.","journal-title":"Curr Hypertens Rep"},{"issue":"8","key":"2343_CR53","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s11906-016-0670-5","volume":"18","author":"FL Ng","year":"2016","unstructured":"Ng FL, Saxena M, Mahfoud F, Pathak A, Lobo MD. Device-based therapy for hypertension. Curr Hypertens Rep. 2016;18(8):61.","journal-title":"Curr Hypertens Rep"},{"issue":"5","key":"2343_CR54","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S0895-7061(99)00005-9","volume":"12","author":"JD Blumenfeld","year":"1999","unstructured":"Blumenfeld JD, Sealey JE, Mann SJ, Bragat A, Marion R, Pecker MS, et al. Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects. Am J Hypertens. 1999;12(5):451\u20139.","journal-title":"Am J Hypertens"},{"issue":"21","key":"2343_CR55","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1161\/01.CIR.0000131449.94713.AD","volume":"109","author":"M Azizi","year":"2004","unstructured":"Azizi M, Menard J. Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. Circulation. 2004;109(21):2492\u20139.","journal-title":"Circulation"},{"key":"2343_CR56","doi-asserted-by":"crossref","unstructured":"Nobre F. et al. VI Brazilian guidelines on hypertension. Arq Bras Cardiol. 2010;95(1 Suppl):1\u201351. \n                    http:\/\/dx.doi.org\/10.1590\/S0066-782X2010001700001\n                    \n                  .","DOI":"10.1590\/S0066-782X2010001700001"},{"key":"2343_CR57","unstructured":"Nobre F, Mion Jr. D, Gomes MAM, et al. V Guidelines for ambulatory blood pressure monitoring (ABPM) and III Guidelines for home blood pressure monitoring (HBPM). Arq Bras Cardiol. 2011;97(3 Suppl)3:1\u201324. \n                    http:\/\/dx.doi.org\/10.1590\/S0066-782X2011001800001\n                    \n                  ."}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-017-2343-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,11]],"date-time":"2019-02-11T19:34:06Z","timestamp":1549913646000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-017-2343-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,12]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["2343"],"URL":"https:\/\/doi.org\/10.1186\/s13063-017-2343-3","relation":{},"ISSN":["1745-6215"],"issn-type":[{"type":"electronic","value":"1745-6215"}],"subject":[],"published":{"date-parts":[[2018,2,12]]},"assertion":[{"value":"10 November 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study protocol has been approved by the Research Ethics Committee of FAMERP, S\u00e3o Paulo, Brazil, which is accredited by the Office of Protection of Human Research as an Institutional Review Board (CAAE n\u00b033943014.6.0000.5415, n\u00b0 870.093) and will comply with the described criteria (Additional files  and ).Written informed consent was obtained from each patient\/participant for publication of their individual details and accompanying images in this manuscript. The consent form is held by the authors\/by the authors\u2019 institution\/in the patients\u2019 clinical notes and is available for review by the Editor-in-Chief.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"101"}}